Gene editing · Gene editing: serine protease inhibitor A1 (alpha-1 antitrypsin) (SERPINA1) · developed by CRISPR Therapeutics
CTX460 is a lipid nanoparticle formulation of a synthetic nucleotide template polymerase (SyNTase) editor that edits the SERPINA1 gene in vivo. It is being studied in adults with emphysema associated with severe alpha-1 antitrypsin deficiency.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07850076 | Phase 1/2 | Alpha-1 Antitrypsin Deficiency (AATD) | Recruiting | CRSP |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Alpha-1 Antitrypsin Deficiency (AATD)
Updated Nov 8, 2026. Something wrong or missing? Report it on the CRSP page.
See CRSP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CRSP catalysts and pipeline →